Xenon Pharmaceuticals reported a positive Phase 3 X-Tole2 study for azetukalner, a KV7 potassium channel opener, with large placebo-adjusted reductions in focal-onset seizure frequency and a tolerable safety profile. The company said the result exceeded expectations and plans to file for FDA approval in the third quarter. Investors reacted strongly to the readout and analysts noted the drug’s oral, once-daily profile and combination potential. Xenon highlighted dose-dependent adverse events but positioned the lower dose as commercially attractive given efficacy and tolerability trade-offs.